Sungkyunkwan University

NEO Battery Materials Announces Appointment of Dr. Dongmok Whang as New Director

Retrieved on: 
Wednesday, April 3, 2024
NEO, Nanotechnology, Research, School, KBIA, Engineering, Samsung, OTC, LG Energy Solution, Ministry, Sungkyunkwan University, Silicon

Dr. Whang commented, “It is a great pleasure to be more deeply involved with the Company that is at the forefront of revolutionizing battery technology.

Key Points: 
  • Dr. Whang commented, “It is a great pleasure to be more deeply involved with the Company that is at the forefront of revolutionizing battery technology.
  • Only three years into R&D, NEO’s pace of performance optimization has been outstanding, considering that battery materials development is a tedious, taxing process.
  • NEO Battery Materials is pleased to announce that it has joined the Korea Battery Industry Association (“KBIA”).
  • Since its inception, the association supported the rise to prominence in the international battery market and organized the world’s leading battery conference, InterBattery.

IonQ and South Carolina Quantum Enter Strategic Agreement to Advance a Quantum Ecosystem in South Carolina

Retrieved on: 
Tuesday, March 19, 2024
Software, Mobile, Wireless, Networks, Other Defense, Internet, Contracts, Hardware, Data Management, Technology, Defense, Semiconductor, Nanotechnology, QLab, Partnership, Education, Information, Entrepreneurship, University, Understanding, Communication, Information science, Workforce, Memorandum, Sungkyunkwan University, Government, ICT, Microscope

IonQ (NYSE: IONQ), a leader in the quantum computing industry, today announced it has entered a strategic agreement with South Carolina Quantum (SC Quantum) to provide world-class quantum computing capabilities and professional services to SC Quantum partners, including academic institutions.

Key Points: 
  • IonQ (NYSE: IONQ), a leader in the quantum computing industry, today announced it has entered a strategic agreement with South Carolina Quantum (SC Quantum) to provide world-class quantum computing capabilities and professional services to SC Quantum partners, including academic institutions.
  • As part of the agreement, IonQ and SC Quantum will partner to develop quantum-specific academic coursework for training future members of the quantum economy.
  • SC Quantum will also partner with IonQ to accelerate the introduction of quantum technologies within enterprises, startups, and industries across South Carolina.
  • In 2023, South Carolina earmarked millions for SC Quantum to develop a quantum-focused workforce and build quantum-smart technologies in the state.

SolidVue, Korea's Exclusive Developer of LiDAR Sensor Chips Showcasing World-Class Technological Capabilities

Retrieved on: 
Tuesday, December 19, 2023
Photon, Conference, SPAD, Solid, Multimedia, UNIST, Robotics, City, International, Semiconductor, Sungkyunkwan University, Electronics, ISSCC, Exhibition, CMOS, Light, Socs, VCS, Growth, Investment, Single-photon avalanche diode, Video game

Established in 2020, SolidVue focuses on designing SoCs (System-on-Chip) for LiDAR sensors that comprehensively assesses the shapes and distances of surrounding objects.

Key Points: 
  • Established in 2020, SolidVue focuses on designing SoCs (System-on-Chip) for LiDAR sensors that comprehensively assesses the shapes and distances of surrounding objects.
  • Jaehyuk Choi, the CEO of SolidVue, disclosed the company's development of Solid-State LiDAR sensor chips, aiming to replace all components of traditional mechanical LiDAR with semiconductors.
  • This innovation is expected to reduce volume by up to one-tenth and costs by around one-hundredth compared to the aforementioned mechanical LiDAR.
  • Utilizing its proprietary CMOS SPAD (Single Photon Avalanche Diode) technology, SolidVue's LiDAR sensor chips flawlessly detect even minute particles of light, enhancing measurement precision.

New Study Finds Significant Correlation Between Masimo ORi™ and Arterial Partial Pressure of Oxygen During One-Lung Ventilation

Retrieved on: 
Monday, December 11, 2023
Biotechnology, Surgery, Health, Pharmaceutical, Health Technology, Odds ratio, Samsung Medical Center, De novo, Blood, OLV, Sungkyunkwan University, Hypoxemia, Risk, MASI, Patient, Multimedia, Journal, FDA, Hyperoxia, Oxygen, Blood gas tension, Perioperative, Ori, Oxygen saturation (medicine), Receiver operating characteristic, Medical device, Medical imaging, Anesthesia, ROC

ORi is trended continuously with SpO2 as a unit-less index between 0.00 and 1.00 to extend the visibility of the patient oxygenation beyond SpO2 under supplemental oxygen.

Key Points: 
  • ORi is trended continuously with SpO2 as a unit-less index between 0.00 and 1.00 to extend the visibility of the patient oxygenation beyond SpO2 under supplemental oxygen.
  • During anesthesia, ORi was monitored using Masimo RD rainbow SET® Pulse CO-Oximetry sensors, and blood gas analysis was performed 15 minutes after OLV was initiated.
  • Of the 11 potential predictors for PaO2
  • The researchers concluded, “ORi values during one-lung ventilation were significantly correlated with PaO2 measured simultaneously.

Treatment with RYBREVANT® (amivantamab-vmjw) and Lazertinib Plus Chemotherapy Showed Durable Progression-Free Survival in Patients with Previously Treated EGFR-Mutated Advanced Non-Small Cell Lung Cancer

Retrieved on: 
Monday, September 11, 2023
WCLC, Neutropenia, Bispecific monoclonal antibody, Janssen Pharmaceuticals, Neoplasm, Samsung Medical Center, Drug, Lung cancer, International Association, TKI, Medicine, NSCLC, Carboplatin, PFS, Trial of the century, Rash, Amivantamab, HIV disease progression rates, Patient, EGFR, MET, Johnson & Johnson, Sungkyunkwan University, Abstract, Pemetrexed, Safety, Disease, Pharmaceutical industry

SINGAPORE, Sept. 11, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced follow-up results from the Phase 1b/2 CHRYSALIS-2 study cohort evaluating the safety and tolerability of the combination of RYBREVANT® (amivantamab-vmjw), a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition (MET), with lazertinib, an oral third-generation EGFR tyrosine kinase inhibitor (TKI), plus platinum-based chemotherapy (carboplatin and pemetrexed) in patients with relapsed/refractory non-small cell lung cancer (NSCLC) and EGFR mutations. These findings are being presented at the International Association for the Study of Lung Cancer (IASLC) 2023 World Congress on Lung Cancer (WCLC) from September 9-12 in Singapore.1

Key Points: 
  • Resistance in patients is typically diverse and polyclonal, meaning their tumors can have more than one type of resistance caused by different pathways.
  • Results from the RYBREVANT®, lazertinib and chemotherapy combination cohort (n=20), were featured in a mini oral presentation ( Abstract #MA13.06 ) at the IASLC 2023 WCLC.
  • Five patients were treated beyond progression, with a median incremental treatment duration of 4.2 months.
  • "These results provide important insights into the treatment of patients with advanced non-small cell lung cancer with EGFR-mutated disease who have progressed on the current standard of care.

Universal Display Corporation Announces Recipients of the 2023 UDC Innovative Research and Pioneering Technology Awards at IMID Korea

Retrieved on: 
Tuesday, August 29, 2023
Consumer Electronics, Other Energy, Technology, Audio, Video, Energy, Hardware, Telecommunications, Lighting, Electronics, IMID, Health care, Organic electronics, Universal Display Corporation, Gachon University, Electronics and Telecommunications Research Institute, Multimedia, Research, PHOLED, KAIST, Asan Medical Center, ETRI, 1957 International Meeting of Communist and Workers Parties, UDC, Sungkyunkwan University, OLED, KIDS, Knowledge, Television, Cryptocurrency, Diabetes

Universal Display Corporation (Nasdaq: OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, announced today the recipients of the UDC Innovative Research Award in Organic Electronics & Display and the UDC Pioneering Technology Award in Organic Electronics & Display.

Key Points: 
  • Universal Display Corporation (Nasdaq: OLED) (UDC), enabling energy-efficient displays and lighting with its UniversalPHOLED® technology and materials, announced today the recipients of the UDC Innovative Research Award in Organic Electronics & Display and the UDC Pioneering Technology Award in Organic Electronics & Display.
  • These awards were presented at the 23rd International Meeting on Information Display (IMID 2023) conference on August 24th in Busan, Korea by Dr. Mike Weaver, Vice President of PHOLED R&D of Universal Display Corporation.
  • We congratulate the UDC Innovative Research Award and UDC Pioneering Technology Award recipients and applaud all the researchers for their contributions in the growing field of organic electronics and displays.
  • The UDC awards recognize outstanding individuals or teams that have demonstrated innovative ideas or research initiatives impacting the organic electronic and display industries.

New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached after 33.6 Months of Follow-Up with First-Line Use of RYBREVANT® (amivantamab-vmjw) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Muta

Retrieved on: 
Sunday, June 4, 2023
Antigen, Neoplasm, IV, Samsung Medical Center, Progression-free survival, SC, Safety, DOR, Drug, Pharmacokinetics, TKI, Medicine, NSCLC, Antibody, IRR, PFS, IHC, ASCO, Incidence, Amivantamab, American Society of Clinical Oncology, HIV disease progression rates, Patient, Standard of care, EGFR, Janssen Pharmaceuticals, Annual general meeting, MET, Immunohistochemistry, Trial of the century, Sungkyunkwan University, Abstract, Society, Pharmaceutical industry

CHICAGO, June 4, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term results from the CHRYSALIS study, which showed the combination of RYBREVANT® (amivantamab-vmjw) and lazertinib*, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), was associated with sustained antitumor activity as a first-line treatment in patients with EGFR-mutated non-small cell lung cancer (NSCLC) (Abstract #9134).1 These findings and additional data, including an analysis of predictive biomarkers from Cohort D of the Phase 1/1b CHRYSALIS-2 study evaluating a chemotherapy-free regimen of RYBREVANT® in combination with lazertinib (Abstract #9013)2 and updated safety results from the Phase 1 PALOMA study evaluating the subcutaneous (SC) administration of RYBREVANT® as a monotherapy (Abstract #9126)3 were presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.   

Key Points: 
  • The estimated PFS rate was 85 percent after one year, 65 percent at two years and 51 percent at three years.
  • "These long-term data for amivantamab and lazertinib introduce the potential for this combination therapy to be used as first-line treatment for this patient population."
  • Data from Cohort D of the Phase 1/1b CHRYSALIS-2 study, which enrolled such patients, were highlighted in an oral presentation at ASCO this year.
  • "We look forward to continuing to evaluate the full potential of RYBREVANT in our ambition to make this novel therapy available earlier in the treatment paradigm for these patients and improve cancer care."

NAODA Partners With NYU and SKKU for Global Game Development Contest

Retrieved on: 
Thursday, June 1, 2023
Consensus, Partnership, New York University Tisch School of the Arts, Korean, Polygon, University, NYU, FLASK, SKKU, School of Arts, IPS, Sungkyunkwan University, Student, School, Video game, New York University

FLASK recently signed a partnership with one of the top-tier universities in South Korea, SKKU.

Key Points: 
  • FLASK recently signed a partnership with one of the top-tier universities in South Korea, SKKU.
  • FLASK will participate as a judge in the 'Global Game Production Contest', which is organized by SKKU's School of Arts in collaboration with the NYU Game Center.
  • The top-ranked games from the contest will be onboarded onto the NAODA platform.
  • "We hope this could be an opportunity for our participation-driven Game-Fi platform NAODA to onboard high-quality and unique games."

GC Genome Announces Publication Demonstrating Feasibility of Liquid Biopsy Technology to Predict Radiation Therapy Response in Solid Tumors

Retrieved on: 
Monday, April 10, 2023
Pancreatic cancer, CIN, BMC, Oncology, DNA, VEGFA, Samsung Medical Center, Genome instability, Nucleic acid thermodynamics, Hepatocellular carcinoma, Sorafenib, CAP, Neoplasm, Survival, University, Cancer, Head, Research, Attention, Genome, Biomarker, Lung, Infant, Plasma, Rare, SM, Patient, Basel, Esophageal cancer, SY, Sungkyunkwan University, Chemoradiotherapy, RT, GC, Disease, Medical imaging, Vaccine, MD

This study adds to the previous studies of prognostic effects of the I-score in various solid tumors, including hepatocellular carcinoma, esophageal cancer, and pancreatic adenocarcinoma1.2.3.

Key Points: 
  • This study adds to the previous studies of prognostic effects of the I-score in various solid tumors, including hepatocellular carcinoma, esophageal cancer, and pancreatic adenocarcinoma1.2.3.
  • Another interesting finding is that minimal residual disease following RT was detected earlier by cfDNA than by imaging studies.
  • "Further additional studies are ongoing to optimize the measurement and analysis of I-scores to predict radiation response accurately.
  • Such statements do not represent any guarantee by GC Genome or its management of future performance and involve known and unknown risks, uncertainties and other factors.

KoverNow Appoints one of Singapore’s Most Prominent Marketing and Data Science Experts as Non-Executive Director

Retrieved on: 
Tuesday, January 31, 2023
Trust, AI, Assistant, Sungkyunkwan University, National University of Singapore, Theory, Data science, Economics, Big data, Intelligence, Behavioral economics, Senior, Icahn Institute for Data Science and Genomic Technology, National university, Associate, NUS, Research, Management, Marketing

Professor Chong, who is a behavioral scientist and data scientist by training, currently carries out research focusing on the challenges of nudging people to adopt useful technology.

Key Points: 
  • Professor Chong, who is a behavioral scientist and data scientist by training, currently carries out research focusing on the challenges of nudging people to adopt useful technology.
  • He joins KoverNow as a non-executive director.
  • Professor Chong’s expertise is in using behavioral and economic principles and data analytics and AI tools.
  • Stephan Kaiser, CEO at KoverNow, said: “Professor Chong has a rich history of advising start-ups in the application of big data and artificial intelligence to their marketing strategies.